Chardan Capital Reaffirms Their Buy Rating on Nightstar Therapeutics Limited


In a report released today, Gbola Amusa from Chardan Capital maintained a Buy rating on Nightstar Therapeutics Limited (NASDAQ: NITE), with a price target of $40. The company’s shares closed yesterday at $14.02.

According to TipRanks.com, Amusa is a 5-star analyst with an average return of 20.2% and a 50.2% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Catalyst Biosciences Inc, and Adverum Biotechnologies.

Currently, the analyst consensus on Nightstar Therapeutics Limited is Moderate Buy and the average price target is $30, representing an 114.0% upside.

In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $20 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $24.94 and a one-year low of $10.01. Currently, Nightstar Therapeutics Limited has an average volume of 25.29K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Nightstar Therapeutics PLC is a clinical-stage gene therapy company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy. The company was founded by Robert MacLaren on July 6, 2017 and is headquartered in London, the United Kingdom.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts